AbbVie Drops 3.1% as New Skyrizi Phase 3 Data Hits the Wire
AbbVie's stock fell 3.1% to $273.85 after Phase 3 AFFIRM trial data for Skyrizi in Crohn's disease was released. Skyrizi is key to AbbVie's growth post-Humira. Investors are awaiting analyst and company commentary on the data.
How this was made
The 30-second read
Why it matters
The data release triggered a 3.1% decline, indicating market skepticism. Traders may look for entry points if the stock oversells, but risk remains until efficacy is confirmed.
Market read
First‑report of pivotal trial data for a major pharma pipeline asset, causing a notable intraday move in a large‑cap stock.
What to watch
Long‑term pipeline beyond Skyrizi and potential label expansion could mitigate the short‑term hit.
Background
AbbVie’s Skyrizi is positioned as the primary growth driver after Humira biosimilar competition. The Phase 3 AFFIRM trial data were released during market hours, prompting an immediate price reaction.
Ticker impact
AbbVie stock fell 3.1% after Phase 3 AFFIRM trial data for Skyrizi in Crohn's disease were released.
likely further downside as doubts about efficacy persist
First‑report of Phase 3 data caused an immediate sell‑off; no offsetting positive news was provided.
Market effects
Biotech sector may see broader caution on late‑stage trial outcomes.
U.S. equities pressured by the drop in a large‑cap pharma stock.
Global biotech investors watch the result for clues on other Crohn's therapies.
Counterpoint
If the AFFIRM data ultimately prove robust, the stock could rebound sharply on a short‑cover rally.
Key entities
- companyAbbVie
U.S. pharmaceutical company developing Skyrizi for Crohn's disease.